Novo Nordisk NVO saw 18% sales growth and 40% operating profit growth at constant currencies in the second quarter, but management reduced 2025 guidance to 8%-14% sales growth and 10%-16% ...

Viatris beats Novo in semaglutide patent feud, clearing hurdle for potential Wegovy generic By Fraiser Kansteiner Jul 24, 2025 10:42am Novo Nordisk Viatris Mylan patent litigation ...

Novo Nordisk stock is in a slump and UBS sees several reasons to no longer be buyers of the weight-loss drugmaker. Most importantly, knockoff versions of so-called GLP-1 drugs appear to be here to ...

By Jacob Gronholt-Pedersen, Stine Jacobsen and Maggie Fick COPENHAGEN (Reuters) -Investors knocked $70 billion off Novo Nordisk's market value on Tuesday after the maker of weight-loss drug Wegovy ...

Investors wiped $70 billion off Novo Nordisk's market value on Tuesday after the maker of weight-loss drug Wegovy issued a profit warning and named a new CEO, as it battles rising competition in ...

Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) is watching its stock plummet 20% in morning trading after slashing its full-year sales and profit outlook for the second time this year. The ...

Reuters FILE PHOTO: A view shows a Novo Nordisk sign outside their office in Bagsvaerd, on the outskirts of Copenhagen, Denmark, July 14, 2025. REUTERS/Tom Little/File Photo ...

Novo Nordisk faces challenges in the competitive GLP-1 market, but its strong brand and R&D create opportunities for long-term investors to capitalize now. Learn more on NVO stock here.

Novo Nordisk, which makes blockbuster weight-loss drugs Ozempic and Wegovy, now expects 2025 sales growth at constant exchange rates of 8% to 14%, down from its early May forecast of 13% to 21%.

Obesity drugmaker Novo Nordisk on Tuesday cut its full-year sales and operating profit forecasts for the second time this year, sending its shares down as much as 17%.

Aug 7 (Reuters) - Shares in Novo Nordisk (NOVOb.CO), opens new tab rose as much as 14% on Thursday after trial data from Eli Lilly's (LLY.N), opens new tab experimental weight-loss pill fell short ...

In Novo Nordisk A/S’s home country of Denmark, the popularity of weight-loss drugs is fueling economic growth, but local retailers are now warning they will take a hit as food consumption declines.